- Elite Trade Club
- Posts
- This MedTech Stock Could Skyrocket 🚀
This MedTech Stock Could Skyrocket 🚀
An up-and-coming stock just found its way to the top of our watchlist.
Chris Dinello
March 19, 2024
Good Morning!
It's Chris from Elite Trade Club, here to give you this morning's premarket trading news.
Let’s get ready to trade!
Markets 📈
Stocks opened the week with a positive session on Monday, although the small-cap Russell 2K posted a loss on the trading day.
|
|
Futures are down in early trading, raising the likelihood of a lower open. S&P 500 contracts are down by almost half-a-point in early trading.
What to Watch Today:
Stocks are locked into a battleground ever since the hotter-than-expected inflation read on February’s CPI report. The market has fluctuated between gains and losses for the past few sessions, and we could see that trend continue through today’s session.
This under-the-radar company could be perfectly positioned to capitalize on a massive early-mover opportunity.
It’s ideally position in an industry with enormous growth potential, and it’s currently working on an up-listing to the Nasdaq.
The stock could see significant inflows if it can complete its move to Nasdaq, and there are several additional catalysts in play as well.
The stars could be aligning for this stock, and it could add up to massive move higher in the coming weeks. Don’t wait until it’s too late.
» Want an Ad-Free Experience + Top Growth Stock Picks? Upgrade Now!
Premarket Highlights 🔎
🏦 Japan's Big Money Moves: Farewell to Negative Rates
IThe Bank of Japan (BOJ) stepped out of the negative interest zone, elevating short-term rates from -0.1% to 0%-0.1%, a first since 2007.
Alongside, it axed yield-curve control and dialed back on asset buying, sending the yen on a wild ride and boosting the Nikkei after a jittery day.
Turning the Page 📄
This pivot marks a drastic shift from decades-long ultra-loose policies aimed at fighting deflation.
With the BOJ setting the scene before the U.S. Federal Reserve's upcoming rate decision, it's a historic recalibration aiming to stimulate price growth within Japan's economy.
Measured Optimism 🌱
BOJ Governor Kazuo Ueda signaled cautious optimism about hitting inflation targets, suggesting the economy's nurturing will continue with accommodative financial conditions.
While hinting at possible future rate adjustments, the journey to 2% inflation remains gradual, emphasizing a continued, careful navigation of Japan's economic revival.
Featured Earnings 💰️
Tencent Music Entertainment Group [TME] ... AM
XPeng [XPEV] ... AM
Caleres [CAL] ... AM
Huya [HUYA] ... AM
Citi Trends [CTRN] ... AM
Smith Douglas Homes [SDHC] ... PM
TeraWulf [WULF] ... PM
Taysha Gene Therapies [TSHA] ... PM
Harrow [HROW] ... PM
Relmada Therapeutics [RLMD] ... PM
Economy 🏗
Housing starts [Feb] ... 8:30a
Building permits [Feb] ... 8:30a
Running Hot 🔥
Gainers
Perspective Therapeutics [CATX] >> +25.3%
Natl. CineMedia [NCMI] >> +25.1%
LiCycle [LICY] >> +28.7%
Decliners
Greenware Tech [GWAV] >> (54.4%)
African Agriculture [AAGR] >> (35.0%)
ShiftPixy [PIXY] >> (32.0%)
Fusion Pharma [FUSN] - Last Close: $10.64
This tiny pharma firm has agreed to be acquired by AstraZeneca [AZN] in a $2.4 billion cash deal.
AstraZeneca will pay $21 for each share of FUSN, plus a contingent value right potentially worth another $3 per share, representing a 97% premium.
FUSN is up 100.1% on more than 1.5 million shares traded.
My Take: AZN paid a hefty premium to snatch up FUSN. It’s looking like 2024 could be an active year for pharma deals, based on what we’ve seen in Q1.
Ontrak [OTRK] - Last Close: $0.19
Ontrak is heating up ahead of a “live fireside chat” at the 36th Annual Roth Conference, scheduled for 4 p.m. Eastern today.
The company announced its participation in the conference last Friday, and trading volume spiked on Monday.
OTRK is a top performer with a 140.4% gain on over 20 million shares traded.
My Take: OTRK appears to be riding a “buy the rumor” rally, but it could see a big pullback if its after-market presentation doesn’t live up to the hype.
Zoomcar [ZCAR] - Last Close: $1.18
Zoomcar is revving up its engine after entering into a strategic partnership with EaseMyTrip, one of India’s largest online travel platforms.
Under the arrangement, Zoomcar’s self-drive cars will be seamlessly integrated into EaseMyTrip’s travel platform.
"Our collaboration with EaseMyTrip is a turning point in our journey to redefine urban mobility for India,” said Zoomcar CEO Greg Moran.
ZCAR is up 46.6% on roughly 12 million shares traded.
My Take: This could prove to be a big deal for ZCAR, especially since the Indian government is so open to supporting self-driving car infrastructure & operations in the country.
Enveric Biosciences [ENVB] - Last Close: $1.10
This tiny biotech is riding high after signing non-binding term sheets to pursue exclusive out-licensing of cannabinoid-COX-2 conjugate compounds.
Enveric’s signed two non-binding term sheets with an unnamed biotech firm. One could deliver up to $61 million in development & sales milestone payments.
The other non-pharmaceutical application term sheet could provide up to $21 million in milestones. Both sheets include varying royalty rates as well.
ENVB is up 34.5% on roughly 12 million shares traded.
My Take: These deal could deliver big windfalls for ENVB, but it will take some time before it all shakes out. I worry we could see a pullback in the coming days, so choose your entry points wisely if you pursue.
That's it for today! Thanks for reading, and good luck out there!
Best Regards,
— Chris D.
Elite Trade Club
Text ELITE to 47121 or click here to get our alerts on your mobile device, and never miss another fast-moving stock!
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
